Market News

Viking Therapeutics, Inc. (VKTX) Reaches $12.74 52-Week High; Financial Federal Has 1 Sentiment

Viking Therapeutics, Inc. (NASDAQ:VKTX) Logo

Financial Federal Corp (FIF) investors sentiment decreased to 1 in Q1 2018. It’s down -0.60, from 1.6 in 2017Q4. The ratio has worsened, as 15 institutional investors opened new and increased holdings, while 15 sold and trimmed holdings in Financial Federal Corp. The institutional investors in our database now possess: 4.11 million shares, down from 4.21 million shares in 2017Q4. Also, the number of institutional investors holding Financial Federal Corp in top ten holdings was flat from 0 to 0 for the same number . Sold All: 4 Reduced: 11 Increased: 10 New Position: 5.

The stock of Viking Therapeutics, Inc. (NASDAQ:VKTX) hit a new 52-week high and has $13.76 target or 8.00% above today’s $12.74 share price. The 8 months bullish chart indicates low risk for the $744.44 million company. The 1-year high was reported on Jun, 16 by Barchart.com. If the $13.76 price target is reached, the company will be worth $59.56 million more. The stock increased 10.49% or $1.21 during the last trading session, reaching $12.74. About 6.08 million shares traded or 107.38% up from the average. Viking Therapeutics, Inc. (NASDAQ:VKTX) has risen 320.16% since June 16, 2017 and is uptrending. It has outperformed by 307.59% the S&P500. Some Historical VKTX News: ; 07/03/2018 – VIKING: VK5211 TRIAL ACHIEVES PRIMARY, SECONDARY ENDPOINTS; 19/03/2018 – Viking Therapeutics at Investor Day Hosted By H.C. Wainwright; 07/03/2018 – Viking Therapeutics: 4Q Net Loss Rises on Increase in Research, Administrative Expenses; 26/03/2018 – Viking Therapeutics Coverage Assumed by H.C. Wainwright at Buy; 09/05/2018 – Viking Therapeutics: IND-enabling Work Underway for VK0214 in X-linked Adrenoleukodystrophy, Proof-Of-Concept Study to Begin 1H 2019; 07/03/2018 – $VKTX Ph2 NAFLD data pushed back from 1H18 to 2H18. -; 15/05/2018 – Arrowmark Partners Buys 3.2% Position in Viking Therapeutics; 15/05/2018 – Polar Capital Buys New 1.5% Position in Viking Therapeutics; 07/03/2018 Viking Therapeutics 4Q Loss/Shr 14c; 09/05/2018 – Viking Therapeutics 1Q Loss/Shr 10c

Analysts await Viking Therapeutics, Inc. (NASDAQ:VKTX) to report earnings on August, 8. They expect $-0.12 earnings per share, up 42.86% or $0.09 from last year’s $-0.21 per share. After $-0.10 actual earnings per share reported by Viking Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 20.00% negative EPS growth.

More notable recent Viking Therapeutics, Inc. (NASDAQ:VKTX) news were published by: Seekingalpha.com which released: “Viking Therapeutics: Hallmark Moment” on June 13, 2018, also Seekingalpha.com with their article: “Viking Therapeutics: What Now After ‘Yuge’ Rally?” published on June 12, 2018, Benzinga.com published: “Maxim Explains Viking Therapeutics’ Sympathy Move With Madrigal” on June 03, 2018. More interesting news about Viking Therapeutics, Inc. (NASDAQ:VKTX) were released by: Globenewswire.com and their article: “Investor Expectations to Drive Momentum within NovoCure, Canada Goose, Telephone and Data, FMC, MobileIron …” published on June 15, 2018 as well as Nasdaq.com‘s news article titled: “3 Growth Stocks at Deep-Value Prices” with publication date: June 15, 2018.

Among 5 analysts covering Viking Therapeutics (NASDAQ:VKTX), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Viking Therapeutics has $1500 highest and $5.0 lowest target. $11.63’s average target is -8.71% below currents $12.74 stock price. Viking Therapeutics had 16 analyst reports since April 7, 2016 according to SRatingsIntel. The stock has “Buy” rating by Maxim Group on Tuesday, May 24. As per Thursday, April 7, the company rating was initiated by H.C. Wainwright. H.C. Wainwright maintained it with “Buy” rating and $700 target in Monday, July 17 report. The company was maintained on Wednesday, July 12 by Maxim Group. As per Thursday, March 8, the company rating was maintained by Roth Capital. Laidlaw maintained it with “Buy” rating and $10 target in Thursday, August 11 report. Roth Capital initiated the shares of VKTX in report on Tuesday, November 21 with “Buy” rating. H.C. Wainwright reinitiated Viking Therapeutics, Inc. (NASDAQ:VKTX) rating on Friday, November 10. H.C. Wainwright has “Buy” rating and $7 target. H.C. Wainwright maintained Viking Therapeutics, Inc. (NASDAQ:VKTX) rating on Friday, June 1. H.C. Wainwright has “Buy” rating and $1500 target. The firm has “Buy” rating given on Thursday, August 10 by H.C. Wainwright.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies for metabolic and endocrine disorders. The company has market cap of $744.44 million. The Company’s lead clinical program is VK5211, an orally available drug candidate, which is in a phase II clinical trials for acute rehabilitation following non-elective hip fracture surgery. It currently has negative earnings. The firm also develops VK2809, an orally available, tissue, and receptor-subtype selective agonist of the thyroid beta receptor for the treatment of hypercholesterolemia and fatty liver disease, as well as for the orphan indication glycogen storage disease type Ia; and VK0214 for the treatment of orphan indication X-linked adrenoleukodystrophy, a rare X-linked, inherited neurological disorder.

More news for First Trust Energy Infrastructure Fund (NYSE:FIF) were recently published by: Digitaljournal.com, which released: “First Trust Energy Infrastructure Fund Issues Notice Regarding June 2018 Distribution” on June 15, 2018. Businesswire.com‘s article titled: “First Trust Energy Infrastructure Fund Declares its Monthly Common Share Distribution of $0.11 Per Share for June” and published on May 21, 2018 is yet another important article.

Sterneck Capital Management Llc holds 0.9% of its portfolio in First Trust Energy Infrastructure Fund for 102,167 shares. Punch & Associates Investment Management Inc. owns 292,981 shares or 0.39% of their US portfolio. Moreover, Thomas J. Herzfeld Advisors Inc. has 0.34% invested in the company for 58,172 shares. The California-based Partnervest Advisory Services Llc has invested 0.22% in the stock. Advisors Asset Management Inc., a Colorado-based fund reported 457,967 shares.

Viking Therapeutics, Inc. (NASDAQ:VKTX) Ratings Chart

Leave a Reply

Your email address will not be published. Required fields are marked *